Trellis Bioscience Raises $9M Series C for Calpurbatug Phase 2

Trellis Bioscience closed a $9M Series C financing to advance calpurbatug (TRL1068), a native human monoclonal antibody being studied for chronic prosthetic joint infection (PJI). The Redwood City, California-based clinical-stage biotechnology company said the round brings total equity financing to approximately $35M and supports completion of a Phase 2 trial built around DAIR, short for debridement, antibiotics, and implant retention.

The financing matters because Trellis Bioscience is not pursuing a broad biotech slogan. It is focused on a specific clinical problem where bacterial biofilms can protect pathogens from standard antibiotic therapy, making prosthetic joint infections difficult, expensive, and physically punishing for patients. The company is betting that its CellSpot platform and calpurbatug program can turn native human antibodies into a more practical weapon against antimicrobial resistance.

What Happened

Trellis Bioscience raised $9M in Series C funding with continued participation from New Science Ventures and Easton Capital. New investors include AMR Action Fund, The Doctor Group of Dallas, Texas, and orthopedic surgeons with prosthetic joint infection expertise from U.S. centers of excellence. The company said Junjun Gao, PhD, Principal at AMR Action Fund, joined the Trellis board in connection with the investment.

The proceeds are intended to support the company's ongoing Phase 2 clinical trial of calpurbatug for chronic PJI. The trial evaluates TRL1068 alongside DAIR, a treatment strategy that attempts to preserve the infected implant instead of moving directly to more invasive revision surgery. Trellis said topline Phase 2 results are expected in Q2 2027.

Why This Matters

Most biotech financing rounds are really arguments about uncertainty. Investors are not only buying a story about a market, a molecule, or a platform. They are deciding whether the evidence has improved enough to justify another investment.

Trellis Bioscience has built its work around native human monoclonal antibodies discovered through CellSpot, a platform designed to identify naturally occurring antibodies from human donors. That gives the company a clear strategic narrative: instead of forcing biology to behave like a software roadmap, Trellis is trying to find immune-system solutions that already exist and turn them into therapies for stubborn infectious disease challenges.

Market Context

Prosthetic joint infection is one of the more difficult clinical challenges in medicine because implanted hardware, bacteria, and biofilm create a problem that cannot be solved by simply escalating antibiotic treatment. Trellis says PJI affects more than 25,000 patients annually in the U.S., or roughly 1% to 2% of joint replacement recipients. The company also says managing these infections can exceed $400,000 per patient, making PJI both a patient care challenge and a significant healthcare cost issue.

That is why the AMR Action Fund's participation is strategically meaningful. Antimicrobial resistance is not an abstract policy issue when it appears around implanted hardware, extended hospital stays, complex surgery, and limited therapeutic options. For biotech investors, a company addressing biofilm-associated infections sits at the intersection of clinical need, health economics, and long-duration drug development risk.

Competitive Landscape

Monoclonal antibodies are not new, but Trellis Bioscience is applying them to a narrow and technically demanding infectious disease indication. Calpurbatug targets DNABII proteins that help stabilize bacterial biofilms, and published Phase 1 research described TRL1068 as a native human monoclonal antibody with biofilm-disrupting activity across Gram-positive and Gram-negative species. That makes the program less about another antibody headline and more about whether biofilm disruption can improve the treatment of chronic infections.

The company's CellSpot platform also provides Trellis with a broader discovery framework beyond a single therapeutic candidate. The current financing, however, keeps attention on what matters most for platform companies: whether a platform can translate into clinical proof. Elegant science is valuable, but patients, physicians, regulators, and payers ultimately care about outcomes.

What This Signals

The Trellis Bioscience financing reflects a more selective venture environment where capital remains available for difficult science, but only when investors can see a credible path to the next milestone. Continued support from New Science Ventures and Easton Capital suggests existing backers were willing to continue funding the company after evaluating its clinical and technical progress. AMR Action Fund's participation adds a focused antimicrobial-resistance perspective to the investor syndicate.

For founders outside biotech, the lesson is not that every company should sound more scientific. It is that evidence compounds. Trellis did not raise this round because native human antibodies make for a compelling phrase. It raised it because the company has a defined indication, a named clinical candidate, an active clinical trial, regulatory designations, and enough progress for specialized investors to continue supporting the next stage of development.

The Bigger Industry Shift

Healthcare continues moving toward targeted biological therapies for problems that older pharmaceutical approaches have struggled to solve. At the same time, antimicrobial resistance is forcing hospitals, investors, and policymakers to focus more closely on infections that often sit outside mainstream startup conversations. PJI is not a glamorous market, but it is the kind of painful clinical problem that demonstrates whether biotech innovation is delivering meaningful clinical value.

Whether calpurbatug succeeds will ultimately be determined by clinical data, not fundraising language. What this financing demonstrates is that specialized investors continue to support companies tackling expensive, biologically complex problems when the science has progressed far enough to justify funding the next milestone. In biotechnology, that is often where the real story begins.